This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

AMAG Pharmaceuticals Announces Financial Results For The Third Quarter And Nine Months Ended September 30, 2012

A live webcast of the conference call and accompanying slides will be accessible through the Investors section of the company’s website at www.amagpharma.com beginning today at 8:00 a.m. ET. Following the conference call, the webcast replay will be available today at approximately 10:00 a.m. ET and will be archived on the AMAG Pharmaceuticals, Inc. website until midnight November 30, 2012.

About Feraheme

In the United States, Feraheme® (ferumoxytol) Injection for Intravenous (IV) use is indicated for the treatment of iron deficiency anemia in adult chronic kidney disease (CKD) patients. Feraheme received marketing approval from the U.S. Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the U.S. shortly thereafter. Ferumoxytol received marketing approval in Canada in December 2011, in the European Union in June 2012, and in Switzerland in August 2012. For additional product information, please visit www.feraheme.com.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a specialty pharmaceutical company focused on the development and commercialization of an intravenous iron to treat iron deficiency anemia (IDA). For additional company information, please visit www.amagpharma.com.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc.

Rienso is a registered trademark of Takeda Pharmaceutical Company, Ltd.

1IMS Health Data (in grams) through the period ending September 30, 2012.

               
 
AMAG Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(unaudited, amounts in thousands, except for per share data)
   
Three Months Ended Sept 30, Nine Months Ended Sept 30,
  2012   2011     2012     2011  
Revenues:
Product sales, net $ 16,176 $ 15,802 $ 44,304 $ 39,905
License fee, collaboration and royalty revenues   1,566   1,753     19,930     6,437  
Total revenues   17,742   17,555     64,234     46,342  
 
Operating costs and expenses (1):
Cost of product sales 4,323 2,669 10,193 7,792
Research and development expenses 5,260 14,894 25,393 45,155
Selling, general and administrative expenses 12,160 17,230 40,442 53,690
Restructuring expense   562   -     1,620     -  
Total operating costs and expenses   22,305   34,793     77,648     106,637  
 
Operating income (loss) (4,563 ) (17,238 ) (13,414 ) (60,295 )
 
Interest and dividend income, net 295 378 1,026 1,390
Other income (expense)   2   14     (1,469 )   (194 )
Net income (loss) before income taxes (4,266 ) (16,846 ) (13,857 ) (59,099 )
Income tax benefit   299   215     793     611  
 
Net income (loss) $ (3,967 ) $ (16,631 ) $ (13,064 ) $ (58,488 )
 
Net income (loss) per share - basic and diluted $ (0.19 ) $ (0.78 ) $ (0.61 ) $ (2.76 )
Weighted average shares outstanding used to compute net loss per share:
Basic and diluted 21,403 21,194 21,374 21,169
 
(1) Stock-based compensation included in operating costs and expenses:
Cost of product sales $ 52 $ 131 $ 198 $ 483
Research and development 473 84 1,420 1,365
Selling, general and administrative 1,525 1,487 3,694 6,950
       
 
AMAG Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited, amounts in thousands)
 
September 30, 2012 December 31, 2011

Cash and cash equivalents

$ 42,900 $ 63,474
Short-term investments 167,943 148,703
Accounts receivable 7,363 5,932
Inventories 12,227 15,206
Receivable from collaboration 777 428
Assets held for sale 2,300 -
Other current assets   7,627   6,288
Total current assets 241,137 240,031
 
Net property, plant & equipment 3,411 9,206
Long-term investments - 17,527
Other assets   460   460
 
Total assets $ 245,008 $ 267,224
 
Accounts payable $ 3,620 $ 3,732
Accrued expenses and other short-term liabilities 16,674 28,916
Deferred revenues   7,250   6,346
Total current liabilities 27,544 38,994
 
Deferred revenues 40,624 45,196
Other long-term liabilities   2,136   2,438
Total long-term liabilities 42,760 47,634
 
Total stockholders’ equity   174,704   180,596
 
Total liabilities and stockholders’ equity $ 245,008 $ 267,224

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, our belief that “we can do better,” our expectation to submit a supplemental new drug application to the U.S. Food and Drug Administration by the end of 2012, our progress in our search to acquire additional products and our expected financial results for the 2012 fiscal year, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Stock quotes in this article: AMAG 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs